Neurocrine Biosciences, Inc.

Please stand by. Your program is about to begin. Should you need audio assistance during today's program, please press star zero. Good day, everyone, and welcome to today's Neurocrime Biosciences Report's second quarter results. At this time, all participants are in a listen-only mode. Later, you will have an opportunity to ask questions during the question-and-answer session. You may register to ask a question at any time by pressing the star and 1 on your touchtone phone. Please note this call may be recorded, and I will be standing by should you need any assistance. It is now my pleasure to turn today's program over to Todd Tushla, Vice President of Investor Relations.

Good morning and welcome to Newark Run's second quarter 2023 earnings call. Today I'm joined by Kevin Gorman, our chief executive officer, Matt Abernathy, our chief financial officer, Irie Roberts, our chief medical officer, Eric Benevich, our chief commercial officer, and Kyle Gano, our chief business development and strategy officer. During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After prepared remarks, we will jump into Q&A. With that, I'll turn the call over to Kevin Vorman.

Thank you, Todd, and good morning, everyone. It's a pleasure to be here this morning. We've had a very strong first half of the year, as you can see from our press release this morning. We are raising our guidance, so what was previously the high end of the range is now the bottom of the range. Very strong performance and very proud of our commercial team out there with Ingresa. We're now set up for a really exciting second half of the year. We have multiple readouts coming from our pipeline led by our PDUFA date for Ingresa and the Korea associated with Huntington. We have a focal onset seizure and data coming out, anhedonia data coming out. And last but not least at all, is the CAH studies both in the adult and in the pediatric population and Irie's going to have a lot more to say about that a little later and we'll also be taking your questions on that so quite a bit going on here it's all been very nice thus far so I'm really looking for the second half of the year and right now I'm going to turn it over to Matt good morning